ArticleInternational journal of environmental research and public health2022
Nationwide Long-Term Evaluation of Polypharmacy Reduction Policies Focusing on Older Adults in Japan.
Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Factors associated with family caregivers' attitudes toward deprescribing in long-term care facilities: a cross-sectional study in South Korea.BMC geriatrics · 2026Article
- Pharmacist-Led Deprescribing Interventions for Older Adults with Polypharmacy: A Retrospective Cohort Study of Community Pharmacy Practice in Japan.Drugs & aging · 2026Article
- Chronic comorbidities, concomitant medications, and treatment patterns of chronic hepatitis B patients receiving nucleos(t)ide analogue therapy: a hospital claims database study in Japan.BMC infectious diseases · 2026Observational
- Association between polypharmacy and the risk of requiring long-term care among community-dwelling older residents: A retrospective cohort study.Journal of general and family medicine · 2025Article
- Polypharmacy and Its Spatial Clustering in Japan: An Ecological Study of the Standardized Polypharmacy Ratio.Cureus · 2025Article
- Prevalence of urgent hospitalizations caused by adverse drug reactions: a cross-sectional study.Scientific reports · 2024Article
- Literature Review of Studies Using the National Database of the Health Insurance Claims of Japan (NDB): Limitations and Strategies in Using the NDB for Research.JMA journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polypharmacy is a serious health issue for older adults worldwide, including in Japan, which has a rapidly aging society. The "Proper Medication Guideline for Older Adults" was published for healthcare providers in May 2018, and polypharmacy reduction incentives were initiated for medical facilities in April 2016 and April 2018. This study identified the long-term reduction in polypharmacy prescriptions focusing on older adults aged 75 years and above from April 2015 to March 2019. The national health insurance claims database, which covers most reimbursement claims in Japan, was selected as the primary data source. In this study, polypharmacy was defined as the simultaneous prescription of seven or more medications or multi-psychotropic medications. The primary outcome was the polypharmacy reduction ratio, which indicates the decrease in polypharmacy proportion based on the number of medications on an outpatient prescription. A total polypharmacy reduction of 19.3% for the "75-89 years" subgroup and 16.5% for the "90 years and above" subgroup was observed over four years. Based on prefecture analysis, the mean values of polypharmacy proportion showed a statistically significant reduction over four years. This study showed a successful nationwide reduction in polypharmacy prescriptions after implementing the polypharmacy management guidelines for older adults and incentive-based policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.